GLAUKOS Corp (GKOS) Form 10-Q — Oct 28, 2026
Glaukos reported Q3 2026 net sales of $211.0 million, up 58% year over year, with gross margin expanding to 85% from 78%.
Key figures
- Eps
- 0.03
- Revenue
- 211030000
- Net Income
- 2018000
- Revenue Yoy
- 58%
- Total Assets
- 979529000
- Cash Position
- 162327000
- Shares Outstanding
- 59196870
- Gross margin q3
- 85%
- Working capital
- 452924000
- Nine month revenue
- 547211000
- Accumulated deficit
- 969272000
- Glaucoma revenue q3
- 151991000
- Revopsis upfront fee
- 10000000
- Corneal health growth q3
- 154%
- Corneal health revenue q3
- 59039000
- Nine month revenue growth
- 50%
- Gross margin prior year q3
- 78%
- Resolution agreement accrual
- 14100000
- Aliso building purchase price
- 15200000
- Revopsis potential milestones
- 875000000
- Operating cash flow nine months
- 40867000
- Huntsville facility project cost
- 42000000
- Cash plus investments and restricted
- 339814000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.